Targeting EZH2 in cancer

By Kimberly H. Kim, C. Roberts. Nature Medicine, 2016

1,343 citations recorded by the source corpus.

Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others. Notably, both gain-of-function and loss-of-function mutations occur in cancers but are associated with distinct cancer types. Here we review the spectrum of EZH2-associated mutations, discuss the mechanisms underlying EZH2 function, and synthesize a unifying perspective that the promotion of cancer arises from disruption of the role of EZH2 as a master regulator of transcription. We further discuss EZH2 inhibitors that are now showing early signs of promise in clinical trials and also additional strategies to combat roles of EZH2 in cancer.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/da992d29641918f478af0913fa318778beb78325

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Bradley E. Bernstein
2. William A. Flavahan
3. Elizabeth Gaskell
4. V. Schirrmacher

Citations in the corpus

• Epigenetic plasticity and the hallmarks of cancer (2017, background): “Evasion of growth suppressors, such as p16/INK4a, canbemediatedby promoter hypermethylation or EZH2 hyperactivity (3, 31).”